Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Controlled and Monocentric Study to Evaluate the Effects of Topical 3% Diclofenac in 2.5% Hyaluronic Acid Gel on Tumor Metabolism in the Treatment of Actinic Keratoses in Immunocompetent and Immunocompromised Patients

Trial Profile

Prospective, Controlled and Monocentric Study to Evaluate the Effects of Topical 3% Diclofenac in 2.5% Hyaluronic Acid Gel on Tumor Metabolism in the Treatment of Actinic Keratoses in Immunocompetent and Immunocompromised Patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Diclofenac/hyaluronic-acid (Primary)
  • Indications Actinic keratosis; Skin cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Mar 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov.record.
    • 02 Jul 2015 According to the against ClinicalTrials.gov.record, planned planned end date changed from 1 Mar 2015 to 1 Oct 2015.
    • 02 Jul 2015 According to the against ClinicalTrials.gov.record, planned primary completion date changed from 1 Dec 2014 to 1 Oct 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top